Bloomberg -- Bristol-Myers Squibb Co. cut the sales force for its second-best-selling drug, the antipsychotic Abilify, as Japanese partner Otsuka Pharmaceutical Co. took over more of the marketing of the medicine.
Bloomberg -- Bristol-Myers Squibb Co. cut the sales force for its second-best-selling drug, the antipsychotic Abilify, as Japanese partner Otsuka Pharmaceutical Co. took over more of the marketing of the medicine.
